#USA #Immunotherapy #Madison, Wisconsin #tumor profiling #Elephas

Elephas Biosciences Boosts Funding to Amplify Tumor Profiling Technology

Elephas Biosciences Corporation, a pioneering entity in the field of cancer treatment, has successfully secured $40 million in Series B-2 funding. This significant investment, announced on November 6, 2025, emphasizes the confidence existing investors have in Elephas's innovative approach to live tumor profiling.

The funding round was populated by a host of notable investors including Northpond Ventures, ARCH Venture Partners, and the State of Wisconsin Investment Board, among others. This newly acquired capital will play a crucial role in propelling the launch and commercialization of the proprietary Elephas Live™ platform, slated for release as a laboratory developed test (LDT) in 2026.

The Elephas Live platform is ingeniously designed to functionally profile ex vivo live tumor biopsies, preserving the essential tumor microenvironment. This preservation is vital, as it facilitates a distinctive approach to overcoming tumor heterogeneity, thus enabling predictions on the efficacy of immunotherapy treatments.

Maneesh Arora, the founder and CEO of Elephas, expressed profound gratitude and excitement regarding the funding achievement, noting, “This financing milestone underscores the strong investor confidence in the promise of Elephas and our shared mission to improve the lives of those affected by cancer.” Arora further emphasized the progress made throughout the year and the robust momentum the company is entering 2026 with.

The funding comes during a pivotal time for Elephas, highlighting its remarkable advancements in immunotherapy response prediction technologies. The company is acutely aware of the pressing challenge posed by cancer, which stands as one of the leading causes of death across the globe. Projections indicate that the number of cancer patients may triple by 2060.

Despite a marked increase in the immunotherapy options available today, only about 20% of patients undergoing these treatments actually derive a beneficial response. Moreover, a significant number of individuals who might benefit from therapies are often not eligible due to the absence of precise predictive biomarkers. This glaring gap in effective treatment assessments has been a motivation behind Elephas’s development of its advanced tumor profiling platform.

By utilizing a method that conservatively manages tumor heterogeneity, their technology allows for an immediate and accurate characterization of immune responses in patients. This capability positions Elephas to make a profound impact on personalized cancer treatment.

In conjunction with reaching this funding milestone, Elephas has also expanded its Scientific Advisory Board by welcoming Dr. Jérôme Galon, a well-respected figure in the realm of cancer research. Dr. Galon, alongside fellow advisory member Dr. Janis Taube, is expected to engage in a symposium focused on boosting immunotherapy response predictions at the Societies for the Immunotherapy in Cancer (SITC) Annual Meeting on November 8, 2025, in National Harbor, Maryland.

XMS Capital Partners facilitated the funding process, acting as the financial advisor to Elephas during this pivotal round. The collaboration between Elephas and its investors signifies a collective commitment to advancing cancer treatment methodologies and improving patient outcomes on a global scale.

As Elephas Biosciences carves out its role in revolutionizing how immunotherapy responses are predicted, the oncology landscape looks promising, with hopes of enhanced patient care and improved survival rates.

To learn more about Elephas and their groundbreaking technologies, visit Elephas Biosciences or connect with them on LinkedIn.

Conclusion

The $40 million raised by Elephas Biosciences marks a significant milestone not only for the company but for the entire field of oncology. By improving the way immunotherapy efficacy is predicted, Elephas is paving the way for more targeted and effective cancer treatments in the future.

Stay connected with us for more updates on innovations in cancer treatment and advancements in healthcare technology.